This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Exome and Genome Growth Boost WGS' Q2 Earnings?
by Zacks Equity Research
GeneDx is likely to have experienced a Q2 lift, backed by strong Exome and genome test volumes, new indications and strategic tech moves.
IDEXX to Release Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
IDXX eyes a Q2 earnings jump with CAG growth, global pricing gains, and momentum in water and software segments.
Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat?
by Zacks Equity Research
RVTY is likely to see another earnings beat as Diagnostics momentum and Signals Software growth offset tariff headwinds.
Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact?
by Zacks Equity Research
DexCom Q2 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WST Q2 Earnings Preview: Will the Stock's Segmental Edge Hold Up?
by Zacks Equity Research
West Pharmaceutical targets steady Q2 growth as high-value GLP-1 and SmartDose demand drives segment momentum.
GeneDx Holdings Corp. (WGS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
GENEDX HOLDINGS (WGS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DGX Q2 Earnings Preview: Will Advanced Diagnostics Lead Performance?
by Zacks Equity Research
Quest Diagnostics' Q2 results may get a lift from Advanced Diagnostics, new health plan deals and recent acquisitions.
Does GENEDX HOLDINGS (WGS) Have the Potential to Rally 26.17% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for GENEDX HOLDINGS (WGS) points to a 26.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Will Robust MedSurg Performance Fuel Boston Scientific's Q2 Earnings?
by Zacks Equity Research
BSX eyes strong Q2 with MedSurg momentum, solid Cardiovascular growth and benefits from key tech acquisitions.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Zacks Equity Research
COR gains on strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose ongoing risks.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
by Zacks Equity Research
CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.
GeneDx Holdings (WGS) Moves 19.0% Higher: Will This Strength Last?
by Zacks Equity Research
GeneDx Holdings (WGS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks Industry Outlook Highlights CVS Health, BrightSpring Health Services and GeneDx
by Zacks Equity Research
CVS, BrightSpring, and GeneDx are tapping into AI, staffing trends, and precision medicine to drive future healthcare gains.
3 Medical Services Stocks Capitalizing on the Healthcare AI Boom
by Urmimala Biswas
CVS, BTSG and WGS are three medical services stocks tapping into AI and tech-driven care to boost diagnostics, cut costs and drive growth in 2025.
Here's Why ENSG Shares Are Attracting Prudent Investors Now
by Zacks Equity Research
The Ensign Group's 23.8% stock gain, strong earnings outlook and low debt levels are drawing investor attention despite rising costs.
Ensign Enhances Presence With 3 New Acquisitions in 2 States
by Zacks Equity Research
ENSG adds three skilled nursing facilities in Idaho and California, boosting its U.S. footprint and fueling future growth.
Here's Why You Should Hold Cigna Stock in Your Portfolio for Now
by Zacks Equity Research
CI gains 14.7% YTD as Evernorth and Cigna Healthcare drive growth, but rising expenses and debt pose challenges.
Danaher Partners With AstraZeneca to Support Precision Medicine
by Zacks Equity Research
DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.
COO Q2 Earnings Beat, 2025 Sales Outlook Tightened, Stock Down
by Zacks Equity Research
COO's fiscal Q2 earnings and sales beat market expectations on the back of strong growth. Improvement in operating margin bodes well.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Zacks Equity Research
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Wall Street Analysts Predict a 32.62% Upside in GENEDX HOLDINGS (WGS): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 32.6% upside potential for GENEDX HOLDINGS (WGS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Reasons to Retain The Cooper Companies Stock in Your Portfolio Now
by Zacks Equity Research
COO benefits from the strength in its business segments. Its acquisitions are likely to drive the top line. However, a rise in selling, general and administrative expenses is concerning.
Here's Why You Should Add Pediatrix Medical to Your Portfolio Now
by Zacks Equity Research
MD rises 5.6% YTD as earnings beat, hospital deals and lower costs drive growth. The Zacks Rank #2 signals strong near-term prospects.